Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 147

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 147
---
 We have completed and announced the results of two Phase 1 studies in DMG. There is an ongoing Phase 1 investigator-initiated trial in medulloblastoma.

Our clinical assets are supported by three proprietary drug delivery technologies focused on improving bio-delivery and bio-distribution of drugs through either sustained delivery (Q-Sphera TM), direct delivery (MidaSolve TM), or targeted delivery (MidaCore TM):

| · | Our Q-Sphera platform: Our disruptive polymer microsphere microtechnology                                                                
 is used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. |

| · | Our MidaSolve platform: Our innovative oligosaccharide nanotechnology                                         
 is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors. |

| · | MidaCore platform: Our gold nanoparticle nanotechnology is used                                     
 for targeting sites of disease by using either chemotherapeutic agents or immunotherapeutic agents. |

We are currently focused on
our clinical stage assets and there are no active research and development programs.

Revenue. Revenue for
the whole of the Company for the years ended December 31, 2023, 2022 and 2021 is set out below.

|                                                           | (£ in thousands) | Year ended December 31, | 2023 |     |     | 2022 |     |     | 2021 |
|:----------------------------------------------------------|:-----------------|:------------------------|-----:|:----|:----|-----:|:----|:----|-----:|
| Revenue (Europe, including United Kingdom)                |                  |                         |  381 |     |     |  699 |     |     |  578 |
| Revenue (Rest of World)                                   |                  |                         |   -- |     |     |   -- |     |     |   -- |
| Total Revenue from continuing and discontinued operations |                  |                         |  381 |     |     |  699 |     |     |  578 |

| 76 |

Recent Developments

The Committed Equity Financing

On January 17, 2025, we entered into the Purchase Agreement withthe Selling Shareholder, pursuant to which we, subject to the restrictions and satisfaction of the conditions in the Purchase Agreement, have the right, but not the obligation, to sell tothe Selling Shareholder, andthe Selling Shareholder